NasdaqGS:UTHRBiotechs
United Therapeutics (UTHR) Valuation Check As TETON 1 IPF Milestone Expands Tyvaso Outlook
United Therapeutics (UTHR) just hit a key clinical milestone with completion of its Phase 3 TETON-1 study of inhaled treprostinil in idiopathic pulmonary fibrosis, a high-need lung disease that could broaden the Tyvaso franchise.
See our latest analysis for United Therapeutics.
Beyond the TETON-1 update, United Therapeutics’ share price at US$473.66 has recently eased, with a 7 day share price return of a 2.41% decline and a year to date share price return of a 4.64% decline. At the same...